liquidity and operating results;
-- We are subject to corporate integrity agreements and noncompliance may
impede our ability to conduct business with the federal government;
-- Legislative or regulatory initiatives that restrict or prohibit the
PBM industry's ability to use patient identifiable medical information
could limit our ability to use information that is critical to the
operation of our business;
-- Our specialty pharmacy business is highly dependent on our
relationships with a limited number of biopharmaceutical suppliers and
the loss of any of these relationships could significantly impact our
ability to sustain or increase our revenues;
-- Our ability to grow our specialty pharmacy business could be limited
if we do not expand our existing base of drugs or if we lose patients;
-- Our specialty pharmacy business, Medicare Part D offerings and certain
revenues from diabetes testing supplies expose us to increased credit
risk;
-- Changes in industry pricing benchmarks could adversely affect our
financial performance;
-- The terms and covenants relating to our existing indebtedness could
adversely impact our financial performance;
-- Prescription volumes may decline, and our net revenues and
profitability may be negatively impacted, if products are withdrawn
from the market, if prescription drugs transition to over-the-counter
products, or if increased safety risk profiles of specific drugs
result in utilization decreases;
-- We may be subject to liability claims for damages and other expenses
that are not covered by insurance;
-- The success of our business depends on maintaining a well-secured
pharmacy operation and technology infrastructure and failure to
'/>"/>
| SOURCE Medco Health Solutions, Inc. Copyright©2008 PR Newswire. All rights reserved |